PACAP (1-27), human, ovine, rat TFA
CAS No. ——
PACAP (1-27), human, ovine, rat TFA ( PACAP 1-27 TFA )
Catalog No. M29768 CAS No. ——
PACAP (1-27), human, ovine, rat TFA (PACAP 1-27 TFA) is an N-terminal fragment of pacap-38 and an effective PACAP receptor antagonist. The IC50s for rat PAC1, rat VPAC1 and human VPAC2 are 3nm, 2nm and 5nm respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
100MG | Get Quote | Get Quote |
|
200MG | Get Quote | Get Quote |
|
500MG | Get Quote | Get Quote |
|
Biological Information
-
Product NamePACAP (1-27), human, ovine, rat TFA
-
NoteResearch use only, not for human use.
-
Brief DescriptionPACAP (1-27), human, ovine, rat TFA (PACAP 1-27 TFA) is an N-terminal fragment of pacap-38 and an effective PACAP receptor antagonist. The IC50s for rat PAC1, rat VPAC1 and human VPAC2 are 3nm, 2nm and 5nm respectively.
-
DescriptionPACAP (1-27), human, ovine, rat TFA (PACAP 1-27 TFA) is an N-terminal fragment of pacap-38 and an effective PACAP receptor antagonist. The IC50s for rat PAC1, rat VPAC1 and human VPAC2 are 3nm, 2nm and 5nm respectively.(In Vitro):Radioligand receptor binding assays with I-monoiodinated PACAP (1-27), human, ovine, rat confirms the presence of PAC -receptors on AR4-2J cells, since PACAP (1-27), human, ovine, rat and PACAP(1–38) equipotently displaces radioligand binding with a Kd of 1-2 nM, whereas vasoactive intestinal peptide (VIP) is 1000-fold less potent. PACAP (1-27), human, ovine, rat exhibits a distinct and much higher susceptibility to VIP-amino acid substitutions. PACAP (1-27), human, ovine, rat has potency and binding affinity to stimulate IP3 and cAMP formation in AR4-2J cells.(In Vivo):The inhibitory effect of pituitary adenylate cyclase activating polypeptide (PACAP (1-27), human, ovine, rat) on the increase in total pulmonary resistance (RL) causes either by allergen or histamine in anaesthetized, ventilated guinea-pigs is studied. PACAP (1-27), human, ovine, rat given via i.v. infusion (0.045-4.5 nmol/kg/min) dose-dependently reduces the increase in RL caused by inhaled ovalbumin and histamine. At the highest dose, PACAP (1-27), human, ovine, rat prevents the increase in RL caused by ovalbumin and histamine completely. Infusion of PACAP (1-27), human, ovine, rat and the β2-adrenoceptor agonist, salbutamol (0.045-4.5 nmol/kg/min) inhibit the increase in RL similarly, but salbutamol increases the heart rate more than PACAP (1-27), human, ovine, rat.
-
In Vitro——
-
In Vivo——
-
SynonymsPACAP 1-27 TFA
-
PathwayOthers
-
TargetOther Targets
-
RecptorIC50: 3 nM (rat PAC1), 2 nM (rat VPAC1), 5 nM (human VPAC2)
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number——
-
Formula Weight3261.68
-
Molecular FormulaC144H225F3N40O41S
-
Purity>98% (HPLC)
-
SolubilityH2O : 100 mg/mL (30.66 mM; Need ultrasonic)
-
SMILES——
-
Chemical NameSequence:His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-NH2
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Gourlet P, et al. Fragments of pituitary adenylate cyclase activating polypeptide discriminate between type I and II recombinant receptors. Eur J Pharmacol. 1995 Dec 4;287(1):7-11.
molnova catalog
related products
-
Trifludimoxazin
Trifludimoxazin is an inhibitor of protoporphyrinogen oxidase and can be used as a herbicide.
-
Escin
Pentacyclic triterpene saponins, biosynthesized from protoaescigenin and barringtogenol, occurring in the seeds of AESCULUS. It inhibits edema formation and decreases vascular fragility.
-
Fendosal
Fendosal is a non-steroidal anti-inflammatory agent. It is 6.9 to 9.5 times more active than aspirin in the prophylactic and therapeutic adjuvant-induced polyarthritis models of chronic inflammation.